Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605703 · ClinicalTrials.gov registry record · Phase 4
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
A Phase 4 study of Obesity and Overweight, sponsored by WW International.
- Active
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
- 1
- Study location
NCT06605703: Active Phase 4 study of Obesity and Overweight, sponsored by WW International.
NCT06605703 is a Phase 4 study of Obesity and Overweight that is active but no longer recruiting, run by WW International. The registered enrollment target is 226 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06605703, a Phase 4 study of Obesity and Overweight, is active but no longer recruiting, sponsored by WW International.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
- 1
- Study location
Study Summary
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
Primary Outcome
Measurement of weight using a bluetooth body weight scale
Conditions Studied
Interventions
- BEHAVIORAL WW Clinic
- DRUG Bupropion-Naltrexone
- DRUG Bupropion-Naltrexone-Metformin
Study Locations (1)
New York
- WW International, Inc - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What the registry record for NCT06605703 still lists
NCT06605703 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which WW Clinic is the first listed.
NCT06605703 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06605703 about?
NCT06605703 is a clinical study titled "A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)". The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
What is the current status of trial NCT06605703?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2024-09-18. Estimated completion is 2026-09.
What conditions does trial NCT06605703 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06605703?
The interventions under investigation include: WW Clinic (BEHAVIORAL), Bupropion-Naltrexone (DRUG), Bupropion-Naltrexone-Metformin (DRUG).
Who is sponsoring clinical trial NCT06605703?
This trial is sponsored by WW International, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605703 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06605703's enrollment target sits among peer trials
226 286th of 1053 higher than 768 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI